A Lacroix1, M Revest2, S Patrat-Delon1, F Lemaître3, E Donal4, A Lorléac'h1, C Arvieux1, C Michelet2, P Tattevin5. 1. Service des maladies infectieuses et réanimation médicale, CHU Pontchaillou, 2, rue Le-Guilloux, 35033 Rennes cedex, France. 2. Service des maladies infectieuses et réanimation médicale, CHU Pontchaillou, 2, rue Le-Guilloux, 35033 Rennes cedex, France; CIC-Inserm 0203, faculté de médecine, université Rennes 1, IFR140, 35000 Rennes, France. 3. Département de pharmacologie clinique, CHU Pontchaillou, 35033 Rennes cedex, France; CIC-Inserm 0203, faculté de médecine, université Rennes 1, IFR140, 35000 Rennes, France. 4. Département de cardiologie et maladies vasculaires, CHU Pontchaillou, 35033 Rennes cedex, France. 5. Service des maladies infectieuses et réanimation médicale, CHU Pontchaillou, 2, rue Le-Guilloux, 35033 Rennes cedex, France; CIC-Inserm 0203, faculté de médecine, université Rennes 1, IFR140, 35000 Rennes, France; Inserm U835, faculté de médecine, université Rennes 1, IFR140, 35000 Rennes, France. Electronic address: pierre.tattevin@chu-rennes.fr.
Abstract
OBJECTIVES: We evaluated the benefit/risk ratio of outpatient parenteral antimicrobial therapy (OPAT) in infective endocarditis (IE). METHOD: We performed an observational retrospective study of definite IE (Duke criteria) treated in an infectious diseases unit in 2012. We compared patients having completed the treatment in hospital (H), and those deemed sufficiently stable, and with adequate home environment, for OPAT. The costs were estimated through hospital bills, and, for OPAT, through the costs of drugs and their administration (material, staff), transportation, and outpatient visits. RESULTS: Eighteen out of 39 consecutive patients presenting with IE received OPAT, with a mean hospital stay of 23.5days (vs 34.7days for H group, P=0.014). No severe adverse event related to OPAT was reported. The global saving was estimated at 267,307euros, or 14,850euros per patient. CONCLUSIONS: OPAT in selected patients presenting with IE seems effective, safe, and reduces costs by approximately 15,000euros per patient.
OBJECTIVES: We evaluated the benefit/risk ratio of outpatient parenteral antimicrobial therapy (OPAT) in infective endocarditis (IE). METHOD: We performed an observational retrospective study of definite IE (Duke criteria) treated in an infectious diseases unit in 2012. We compared patients having completed the treatment in hospital (H), and those deemed sufficiently stable, and with adequate home environment, for OPAT. The costs were estimated through hospital bills, and, for OPAT, through the costs of drugs and their administration (material, staff), transportation, and outpatient visits. RESULTS: Eighteen out of 39 consecutive patients presenting with IE received OPAT, with a mean hospital stay of 23.5days (vs 34.7days for H group, P=0.014). No severe adverse event related to OPAT was reported. The global saving was estimated at 267,307euros, or 14,850euros per patient. CONCLUSIONS:OPAT in selected patients presenting with IE seems effective, safe, and reduces costs by approximately 15,000euros per patient.
Authors: Christoph Kolja Boese; Philipp Lechler; Michael Frink; Michael Hackl; Peer Eysel; Christian Ries Journal: World J Clin Cases Date: 2019-07-26 Impact factor: 1.337
Authors: W Wen; H Li; C Wang; C Chen; J Tang; M Zhou; X Hong; Y Cheng; Q Wu; X Zhang; Z Feng; M Wang Journal: Rev Esp Quimioter Date: 2022-06-02 Impact factor: 2.515
Authors: Priscila R Oliveira; Vladimir C Carvalho; Sergio Cimerman; Ana Lucia Munhoz Lima Journal: Braz J Infect Dis Date: 2017-07-14 Impact factor: 3.257